Regulatory Toxicology and Pharmacology is the official journal of the International Society of Regulatory Toxicology and
Pharmacology. The journal reports significant developments that influence the scientific, statutory, legal, policy, administrative,
and enforcement aspects of health, safety, and environmental regulations. Within such a scope, the journal will consider and publish
commentaries about policy, legal and social issues, as well as economic studies, and scientific findings in toxicology, pharmacology,
epidemiology, ecology, and other disciplines of regulatory significance. The scope of the journal is international.
Submission
of Manuscripts. Manuscripts must be written in clear, grammatical English. Submission to this journal proceeds totally online. Use
the following guidelines to prepare your article. Via the homepage of Regulatory Toxicology and Pharmacology at http://ees.elsevier.com/rtp
you will be guided stepwise through the creation and uploading of the various files. The system automatically converts source files to
a single Adobe Acrobat PDF version of the article, which is used in the peer-review process. Please note that even though manuscript
source files are converted to PDF at submission for the review process, these source files are needed for further processing after acceptance.
All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail and via the author's
home page, removing the need for a hard-copy paper trail.
Contact information:
Regulatory Toxicology and Pharmacology Editorial Office 525 B Street, Suite 1900 San Diego, CA 92101-4495, USA Telephone: (619) 699-6275 Fax: (619) 699-6211
E-mail: rtp@elsevier.com
There are no submission fees or page charges.
Original papers only will be considered.
Manuscripts are accepted for review with the understanding that the same work has not been published, that it is not under consideration
for publication elsewhere, and that its submission for publication has been approved by all of the authors and by the institution where
the work was carried out; further, that any person cited as a source of personal communications has approved such citation. Written authorization
by personal sources may be required at the Editor's discretion. Articles and any other material published in Regulatory Toxicology
and Pharmacology represent the opinions of the authors, unless directly endorsed or authorized, should not be construed to reflect
the opinions of the International Society of Regulatory Toxicology and Pharmacology, the Editors, or the Publisher.
Upon acceptance
of an article, authors will be asked to sign a "Journal Publishing Agreement" (for more information on this and copyright, see http://www.elsevier.com/copyright).
Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding
author confirming receipt of the manuscript together with a "Journal Publishing Agreement" form or a link to the online version of this
agreement.
If material from other copyrighted works is included, the author(s) must obtain written permission from the copyright
owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: contact Elsevier's Rights
Department, P.O. Box 800, Oxford, UK; phone: (+44) 1865 853830, fax: (+44) 1865 853333, e-mail: permissions@elsevier.com.
Requests may also be completed online via the Elsevier homepage (http://www.elsevier.com/locate/permissions).
Conflict
of Interest Statement. In compliance with the National Library of Medicine policy, Regulatory Toxicology and Pharmacology
requires full disclosure of all potential conflicts of interest. At the end of the manuscript text (and in the cover letter of the manuscript),
under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people
or organisations that could inappropriately influence (bias) their work. Affiliation of authors submitting manuscripts in their role
as members of industrial or government organizations may constitute sufficient disclosure. Academic, nonprofit, consulting, advocacy,
and all other authors are asked to disclose all sources of financial and material support for the studies and manuscripts submitted.
If there are no conflicts of interest, the authors should state, "The authors declare that there are no conflicts of interest." Signed
copies of the Regulatory Toxicology and Pharmacology Conflict of Interest policy form are required upon submission. The Conflict
of Interest policy form can be downloaded here. In order to
minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript.
Ethical
Treatment of Subjects. Submission of a manuscript implies that the authors warrant to have complied with institutional policies governing
the ethical treatment of human subjects and animals, and that the authors are ready to share the original approval documents if so requested.
Peer Review. Submitted manuscripts not rejected at first screen will undergo a peer review process that occasionally could
require substantial revision and may last several months, depending on the timeliness of author response.
Letters. A brief
one-printed-page observation may be published under a "Letters" heading with the understanding that only one reply will be
published in a rebuttal. A manuscript intended for publication in Letters or a rebuttal should be so designated when submitted for publication.
Preparation of Manuscript. Authors of scientific reports should make a point to validate whether the data measure what they
claim to have measured or whether they could be distorted by adventitious interferences. Authors should also provide evidence that test
and control conditions differ only on account of the experimental variables tested, or are not affected by spurious confounding conditions.
Conclusions should focus on the most probable explanation of results, but should also endeavor to point out other less apparent but
plausible conclusions. Submissions that are not scientific experimental reports, such as policy positions and reviews, should strive
for range, logical sequence, clarity, and well-articulated conclusions.
The popularity of Regulatory Toxicology and Pharmacology
makes it necessary to severely limit authors' discussions and data presentations in their manuscripts. Because the scope of environmental
toxicology and pharmacology is so great, it is not possible to devote many pages to a single issue.
Use generic names of chemicals
whenever possible. Proprietary names and trademarks should appear only to identify the source of the chemical, and subsequently only
the generic name should be used. All abbreviations, other than those for standard units, should be defined in text or in a footnote.
Abbreviations should be unpunctuated.
Manuscripts should be double-spaced throughout. Pages should be numbered consecutively and organized
as follows:
The title page (p. 1) should contain the article title, authors' names and complete affiliations, footnotes to
the title, and the address for manuscript correspondence (including e-mail address and telephone and fax numbers). Separate word counts
should be provided for abstract, text, and references. A second page containing only the title of the paper should be submitted if the
authors wish to obtain a blind peer review.
The abstract (p. 2) must be a single paragraph that summarizes the main findings
of the paper in less than 200 words. After the abstract a list of up to 10 keywords that will be useful for indexing or searching should
be included.
Format. Flexibility of format is allowed, given the mix of multidisciplinary scientific reports and of policy
and review articles of interest to the journal. Clarity and brevity will be preferred.
References should be cited in the
text by the first author's surname followed by et al. If only two authors are listed, both names should be cited. References should
be listed alphabetically by name. Journal names should follow the style of the latest edition of the Chemical Abstracts Service
Source Index. Only articles that have been published or are in press should be included in the references. Unpublished results
or personal communications should be cited as such in the text.
Gerrity, T.R., Henry, C.J., 1990. Principles of Route-to-Route Extrapolation
for Risk Assessment. Elsevier, New York.
LaPuma, P.T., Brain S. Rhodes, B.S., 2002. Chromate content versus particle size for aircraft
paints. Regul. Toxicol. Pharmacol. 36, 318-324.
Mettam, O.R., Adams, L.B., 1999. How to prepare an electronic version of your article,
in: Jones, B.B., Smith, R.Z. (Eds.), Introduction to the Electronic Age. E-Publishing Inc., New York, pp. 281-304.
Figures
should be in a finished form suitable for publication. Number figures consecutively with Arabic numerals. A detailed guide on electronic
artwork is available on our website: http://www.elsevier.com/artworkinstructions.
Color Figures. Illustrations
in color in the printed issue can be accepted only if the authors defray the cost. However, if together with your accepted article, you
submit usable color figures, then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g.,
ScienceDirect and other sites) regardless of whether these illustrations are reproduced in color in the printed version. For color reproduction
in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. For further information
on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Please note: Because of technical complications that can arise in converting color figures to "gray scale" (for the printed version
should you not opt for color in print), please submit in addition usable black-and-white files corresponding to all the color illustrations.
Tables should be numbered consecutively with Arabic numerals in order of appearance in the text. Type each table double-spaced
on a separate page with a short descriptive title typed directly above and with essential footnotes below.
Preparation of Supplementary
Data. Elsevier now accepts electronic supplementary material (e-components) to support and enhance your scientific research. Supplementary
files offer the Author additional possibilities to publish supporting applications, movies, animation sequences, high-resolution images,
background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of
your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
In order to ensure that your submitted material is directly usable, please ensure that data is provided in one of our recommended file
formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption
for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions. This journal offers electronic submission services and supplementary data files can be uploaded via the homepage of this
journal at http://www.elsevier.com/rtp.
US National Institutes of
Health (NIH) voluntary posting (" Public Access") policy.
Elsevier facilitates author response to the NIH voluntary posting request
(referred to as the NIH "Public Access Policy"; see http://www.nih.gov/about/publicaccess/index.htm)
by posting the peer-reviewed author's manuscript directly to PubMed Central on request from the author, 12 months after formal publication.
Upon notification from Elsevier of acceptance, we will ask you to confirm via e-mail (by e-mailing us at NIHauthorrequest@elsevier.com ) that your work has received NIH funding and that you intend to respond to the NIH policy request, along with your NIH award
number to facilitate processing. Upon such confirmation, Elsevier will submit to PubMed Central on your behalf a version of your manuscript
that will include peer-review comments, for posting 12 months after formal publication. This will ensure that you will have responded
fully to the NIH request policy. There will be no need for you to post your manuscript directly with PubMed Central, and any such posting
is prohibited.
PDF proofs will be sent by e-mail to the corresponding author. To avoid delay in publication, only necessary
changes should be made, and corrections should be returned within 48 hours.
